Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eptinezumab in Pediatric Participants with Episicodic Migraine
2022-502538-14-00Phase 3Authorised
- Sponsor
- Lundbeck
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial in migraine comparing Eptinezumab (Vyepti) with Placebo (NaCl 0.9%) (2 arms). Primary endpoint: Change from baseline in the number of monthly migraine days (MMDs) averaged over weeks 1–12. Planned start Sep 2023; status: authorised.
02
Drugs
eptinezumab
03
Conditions
migraine
Beyond the preview
Go deeper on 2022-502538-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502538-14-00.